Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Evelina Pogoriler"'
Autor:
Gerd Ritter, Jedd D. Wolchok, Mario Sznol, Teresa S. Rasalan, Sacha Gnjatic, Lloyd J. Old, Ruth Halaban, Stephanie L. Terzulli, Humilidad F. Gallardo, Evelina Pogoriler, Deborah Kuk, Jianda Yuan, Matthew Adamow, Brian A. Ginsberg, Achim A. Jungbluth, Katherine S. Panageas, James P. Allison, Yinyan Xu, Erika Ritter
Publikováno v:
Proceedings of the National Academy of Sciences. 108:16723-16728
Ipilimumab, a monoclonal antibody against cytotoxic T lymphocyte antigen 4 (CTLA-4), has been shown to improve survival in patients with advanced metastatic melanoma. It also enhances immunity to NY-ESO-1, a cancer/testis antigen expressed in a subse
Autor:
Achim A. Jungbluth, Lloyd J. Old, Gerd Ritter, Geoffrey Y. Ku, Yinyan Xu, Teresa S. Rasalan, Erika Ritter, Ruth Ann Roman, James P. Allison, Humilidad F. Gallardo, Melanie Heywood, Jedd D. Wolchok, Hao Li, Neil H. Segal, Evelina Pogoriler, Sacha Gnjatic, Sarah Powel, Gregor Manukian, Jianda Yuan, Stephanie L. Terzulli
Publikováno v:
Proceedings of the National Academy of Sciences. 105:20410-20415
Blockade of inhibitory signals mediated by cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) has been shown to enhance T cell responses and induce durable clinical responses in patients with metastatic melanoma. The functional impact of anti-CTLA-
Autor:
Ruth-Ann Roman, Sumit K. Subudhi, Margaret K. Callahan, Sapna Tandon, Y. Xu, Arvin Yang, Katherine S. Panageas, Jedd D. Wolchok, Deborah Kuk, A. I. Heine, James P. Allison, Jianda Yuan, Evelina Pogoriler
Publikováno v:
Journal of Clinical Oncology. 29:2505-2505
2505 Background: Ipilimumab is the first agent to demonstrate a survival benefit in patients with metastatic melanoma in a randomized phase III clinical trial. Immune-related adverse events (irAEs)...
Autor:
Arvin Yang, Jianda Yuan, Evelina Pogoriler, Jedd D. Wolchok, Brian A. Ginsberg, Ruth-Ann Roman, A. I. Heine, R. F. Kendle
Publikováno v:
Journal of Clinical Oncology. 28:2555-2555
2555 Background: Increasing doses of ipilimumab, an antibody to CTLA-4, is associated with a higher likelihood of clinical benefit. Analysis of pharmacodynamic biomarkers shows the magnitude of absolute lymphocyte count (ALC) increase correlates with